DERMATA THERAPEUTICS INC
COM · CUSIP 249845108
1
institutional holders
-11 vs Q4 2022
$0reported value*
0 new
0 added
0 reduced
11 sold out
net sold ≈ $118.8k (-292.8k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q1 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 10 |
| Q4 2022 | 12 |
| Q1 2023 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 7 | 4 |
| Q1 2023 | 0 | 11 |
Biggest buyers
| None |
Biggest sellers
| Raymond James Financial Services Advisors, Inc. | Sold out | -141.8k |
| UBS Group AG | Sold out | -37.3k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -26.7k |
| WELLS FARGO & COMPANY/MN | Sold out | -24.4k |
| FAS Wealth Partners, Inc. | Sold out | -12.7k |
| TWO SIGMA SECURITIES, LLC | Sold out | -12.4k |
| Sage Capital Advisors,llc | Sold out | -12.0k |
| TUDOR INVESTMENT CORP ET AL | Sold out | -10.2k |
| HC Advisors, LLC | Sold out | -10.0k |
| Tower Research Capital LLC (TRC) | Sold out | -4.7k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| PROEHL GERALD T 13D · may seek influence -7.2 pts · filed 2025-04-03 | 7.8% |
Holders, Q1 2023
| Manager | Shares | Change |
|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |